


Substitute Form PTO-1449 (Modified) (Patent & Trademark Office)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-411002	Application No. 10/780,394
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Stephen J. Russell et al.	
		Filing Date February 17, 2004	Group Art Unit 1632 1633

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
QN	1	5,736,387	04/07/98	Paul et al.			
	2	5,554,512	09/10/96	Lyman et al.			
	3	5,447,851	09/05/95	Beutler et al.			
QN	4	6,723,561	04/20/04	Russell et al.			


Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
QN	5	WO 92/00376	01/09/92	PCT				
	6	WO 93/00103	01/07/93	PCT				
	7	WO 93/25234	12/23/93	PCT				
	8	WO 94/06920	03/31/94	PCT				
	9	WO 94/27643	12/08/94	PCT				
	10	WO 96/00294	01/04/96	PCT				
QN	11	WO 96/33281	10/24/96	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
QN	12	Anderson et al., "Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-12q24," <u>Cell Growth Differ.</u> , 1991, 2:373-378
	13	Anderson, "Human gene therapy," <u>Nature</u> , 1998, 392:25-30
	14	Bagnis et al., "Retroviral Transfer of the nlsLacZ gene into Human CD34 ⁺ Cell Populations and into TF-1 Cells: Future Prospects in Gene Therapy," <u>Hum. Gene Ther.</u> , 1994, 5:1325-1333
	15	Berardi et al., "Functional Isolation and Characterization of Human Hematopoietic Stem Cells," <u>Science</u> , 1995, 267:104-108
	16	Briones et al., "Retroviral gene transfer into human hematopoietic cells: an <i>in vitro</i> kinetic study," <u>Haematologica</u> , 1999, 84:483-488
	17	Broxmeyer et al., "Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells," <u>Exp. Hematol.</u> , 1995, 23:1121-1129
	18	Einerhand et al., "IL-6 Production by Retrovirus Packaging Cells and Cultured Bone Marrow Cells," <u>Hum. Gene Ther.</u> , 1991, 2:301-306
	19	Kasahara et al., "Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptor Interactions," <u>Science</u> , 1994, 266:1373-1376
QN	20	Krause et al., "CD34: Structure, Biology, and Clinical Utility," <u>Blood</u> , 1996, 87:1-13

Examiner Signature 	Date Considered 8/29/05
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-411002	Application No. 10/780,394
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Stephen J. Russell et al.	
		Filing Date February 17, 2004	Group Art Unit 1632 1633

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
QN	21	Kohn, "Gene therapy for haematopoietic and lymphoid disorders," <u>Clin. Exp. Immunol.</u> , 1997, 107:54-57
	22	Lambrigts et al., "Discordant Organ Xenotransplantation in Primates," <u>Transplantation</u> , 1998, 66(5):547-561
	23	Leitner et al., "Lack of DNA synthesis among CD34 ⁺ cells in cord blood and in cytokine-mobilized blood," <u>Br. J. Haematol.</u> , 1996, 92:255-262
	24	Luskey et al., "Stem Cell Factor, Interleukin-3, and Interleukin-6 Promote Retroviral-Mediated Gene Transfer Into Murine Hematopoietic Stem Cells," <u>Blood</u> , 1992, 80(2):396-402
	25	Markowitz et al., "Construction and use of a safe and efficient amphotropic packaging cell line," <u>Virology</u> , 1988, 167(2):400-406
	26	Maurice et al., "Efficient Gene Delivery to Quiescent Interleukin-2 (IL-2)-Dependent Cells by Murine Leukemia Virus-Derived Vectors Harboring IL-2 Chimeric Envelopes Glycoproteins," <u>Blood</u> , 1999, 94(2):401-410
	27	Morgenstern and Land, "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line," <u>Nucl. Acids Res.</u> , 1990, 18(12):3587-3596
	28	Mullis et al., "Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction," <u>Cold Spring Harb. Symp. Quant. Biol.</u> , 1986, 51:263-273
	29	Nilson et al., "Targeting of retroviral vectors through protease-substrate interactions," <u>Gene Therapy</u> , 1996, 3:280-286
	30	Phillips et al., "Renewed DNA Synthesis in Senescent WI-38 Cells by Expression of an Inducible Chimeric c-fos Construct," <u>J. Cell. Physiol.</u> , 1992, 151:206-212
	31	Russell et al., "Retroviral vectors displaying functional antibody fragments," <u>Nucl. Acids Res.</u> , 1993, 21(5):1081-1085
	32	Takeuchi et al., "Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell," <u>J. Virol.</u> , 1994, 68(12):8001-8007
	33	Thrasher et al., "Restoration of Superoxide Generation to a Chronic Granulomatous Disease-Derived B-Cell Line by Retrovirus Mediated Gene Transfer," <u>Blood</u> , 1992, 80(5):1125-1129
QN	34	Valsesia-Wittmann et al., "Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors," <u>J. Virol.</u> , 1994, 68(7):4609-4619

Examiner Signature 	Date Considered 8/29/05
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	